GLOBAL LIVER INSTITUTE
Congress is entering a very busy work period in September, the last before the November elections. GLI is preparing for its Advanced Advocacy Academy (A3) and subsequent day on Capitol Hill to advocate for legislation!
Thank you for being a part of Liver Cancer News! As we gear up for Liver Cancer Awareness Month next month, we are thrilled to announce the launch of a comprehensive patient toolkit designed to support our community throughout their cancer journey.
With advancements in second-line treatments for PBC in 2024, both current and new treatment options must remain available, so that every patient can choose the treatment that best meets their needs.
New Clinical Practice Guidelines for MASLD, developed jointly by EASL, EASD, and EASO, update the 2016 guidelines to reflect recent advancements.
The Board of Directors of Global Liver Institute (GLI), the premier liver patient advocacy organization, has appointed Larry R. Holden as the organization’s Chief Executive Officer, as of September 2024.
Hepatitis C infection, an infection of the liver by the hepatitis C virus, is a major global health concern, affecting millions.
Clinical practice guidelines are evidence-based recommendations developed through systematic review and consensus to help healthcare providers and patients make informed decisions about the most appropriate treatment options for specific health conditions.
Global Liver Institute (GLI) celebrates the expansion of treatment options for patients with primary biliary cholangitis (PBC) after the U.S. Food and Drug Administration decided to provide accelerated approval of Gilead Science’s seladelpar (Livdelzi®) for primary biliary cholangitis (PBC).
Congress is entering the August recess period. Nevertheless, patients are increasingly signaling to policymakers their frustration related to coverage challenges and over-zealous utilization management practices such as non-medical switching and other barriers to care. And appropriations bills are out for FY 2025!
The recent FDA approval of resmetirom, which offers hope for those with moderate-to-advanced liver scarring, marks a breakthrough in treatment.
Thank you for reading Liver Cancer News! Liver cancer is associated with low five-year survival rates, often due to late-stage diagnosis of the disease.
Ipsen Pharmaceuticals has just shared exciting news for rare liver disease patients with cholestasis.
